Patents by Inventor Mariola Fotin-Mleczek
Mariola Fotin-Mleczek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10988754Abstract: The present invention provides novel artificial nucleic acid molecules encoding at least one antigenic peptide or protein and at least one additional sequence preferably targeting the antigenic peptides or proteins to cellular compartments of interest. Further, the invention provides (pharmaceutical) compositions or vaccines and kits comprising said nucleic acid molecules. The nucleic acid molecules, (pharmaceutical) compositions or vaccines and kits are useful for treating a variety of diseases such as cancer, infectious diseases, autoimmune diseases, allergies or graft-versus host disease.Type: GrantFiled: July 3, 2018Date of Patent: April 27, 2021Assignee: Cure Vac AGInventors: Mariola Fotin-Mleczek, Katja Fiedler, Aleksandra Kowalczyk, Regina Heidenreich
-
Publication number: 20210060175Abstract: The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide has a length of 8 to 15 amino acids and has the empirical formula (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.Type: ApplicationFiled: November 5, 2020Publication date: March 4, 2021Applicant: CureVac AGInventors: Mariola FOTIN-MLECZEK, Patrick BAUMHOF
-
Publication number: 20210046179Abstract: The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)RNA, complexed with a cationic or polycationic compound, and b) at least one free mRNA, encoding at least one therapeutically active protein, antigen, allergen and/or antibody, wherein the immunostimulatory composition is capable to elicit or enhance an innate and optionally an adaptive immune response in a mammal. The inventive immunostimulatory composition may be a pharmaceutical composition or a vaccine. The invention furthermore relates to a method of preparation of the inventive immunostimulatory composition. The invention also relates to the use of the inventive immunostimulatory composition or its components (for the preparation of a pharmaceutical composition or a vaccine) for the treatment of various diseases.Type: ApplicationFiled: June 19, 2020Publication date: February 18, 2021Applicant: CureVac AGInventors: Mariola FOTIN-MLECZEK, Söhnke VOSS
-
Patent number: 10918740Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.Type: GrantFiled: July 19, 2018Date of Patent: February 16, 2021Assignee: CureVac AGInventors: Mariola Fotin-Mleczek, Aleksandra Kowalczyk, Regina Heidenreich, Patrick Baumhof, Jochen Probst, Karl-Josef Kallen
-
Publication number: 20200399322Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g.Type: ApplicationFiled: September 9, 2020Publication date: December 24, 2020Applicant: CureVac AGInventors: Patrick BAUMHOF, Susanne RAUCH, Aleksandra KOWALCZYK, Johannes LUTZ, Edith JASNY, Benjamin PETSCH, Andreas THESS, Thomas SCHLAKE, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Sandra LAZZARO, Fatma FUNKNER, Wolfgang GROSSE
-
Patent number: 10869935Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.Type: GrantFiled: February 4, 2019Date of Patent: December 22, 2020Assignee: CureVac AGInventors: Mariola Fotin-Mleczek, Aleksandra Kowalczyk, Regina Heidenreich, Patrick Baumhof, Jochen Probst, Karl-Josef Kallen
-
Publication number: 20200163878Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.Type: ApplicationFiled: October 26, 2017Publication date: May 28, 2020Inventors: Patrick BAUMHOF, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Michael J. HOPE, Edith JASNY, Sandra LAZZARO, Paulo Jia Ching LIN, Johannes LUTZ, Barbara MUI, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT, Ying TAM
-
Publication number: 20200085943Abstract: The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.Type: ApplicationFiled: August 29, 2019Publication date: March 19, 2020Applicant: CureVac AGInventors: Patrick BAUMHOF, Thomas KRAMPS, Söhnke VOSS, Karl-Josef KALLEN, Mariola FOTIN-MLECZEK
-
Publication number: 20200085852Abstract: The invention concerns the field of genetic vaccination, in particular RNA vaccines. The present invention provides an mRNA for use in the treatment and/or prevention of a disease, wherein the mRNA is administered to the epidermis. Furthermore, the invention provides compositions comprising the mRNA for epidermal administration or kits comprising the mRNA for epidermal administration. Moreover, the invention concerns the medical use of the mRNA or compositions comprising the mRNA, wherein the mRNA or compositions comprising the mRNA are administered to the epidermis.Type: ApplicationFiled: August 5, 2016Publication date: March 19, 2020Inventor: Mariola FOTIN-MLECZEK
-
Publication number: 20200085944Abstract: The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides a combination of an RNA encoding an epitope and immune checkpoint inhibitors. A pharmaceutical composition, vaccine, and kit-of-parts comprising said combination are also provided. Furthermore, the present invention relates to the combination, (pharmaceutical) composition, vaccine or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of cancer, infectious diseases and other diseases and disorders.Type: ApplicationFiled: March 16, 2018Publication date: March 19, 2020Inventors: Regina HEIDENREICH, Katja FIEDLER, Mariola FOTIN-MLECZEK, Aleksandra KOWALCZYK, Knut ELBERS, Melanie WURM
-
Patent number: 10568958Abstract: The present invention is directed to a composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant component and the antigen. The present invention is also directed to the first medical use of such a composition or vaccine composition and to the second medical use of such a composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancer or tumour diseases as defined herein. The present invention furthermore discloses kits comprising such a composition or vaccine composition.Type: GrantFiled: July 8, 2016Date of Patent: February 25, 2020Assignee: CureVac AGInventors: Patrick Baumhof, Karl-Josef Kallen, Mariola Fotin-Mleczek
-
Publication number: 20200030422Abstract: The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.Type: ApplicationFiled: April 15, 2019Publication date: January 30, 2020Applicant: CureVac AGInventors: Mariola FOTIN-MLECZEK, Karl-Josef KALLEN, Jan C. SCHMOLLINGER
-
Publication number: 20200023076Abstract: The present invention relates to a RNA encoding an antibody or a fragment or variant thereof and a composition, in particular a passive vaccine, comprising such an RNA. The present invention further relates to the use of such an RNA or of such a composition for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention also relates to a combination of at least two modified RNA's, in particular wherein one RNA encodes a heavy chain variable region of an antibody and another RNA encodes the corresponding light chain variable region of said antibody.Type: ApplicationFiled: April 28, 2017Publication date: January 23, 2020Inventors: Mariola FOTIN-MLECZEK, Ingmar HOERR
-
Publication number: 20190381155Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.Type: ApplicationFiled: August 29, 2019Publication date: December 19, 2019Applicant: CureVac AGInventors: Mariola FOTIN-MLECZEK, Karl-Josef KALLEN, Jochen PROBST
-
Publication number: 20190343942Abstract: The present invention relates to an RNA encoding a tumor antigen. In particular, the present invention relates to RNA suitable for treatment and/or prophylaxis of cancer and related diseases. The present invention concerns such novel RNA as well as compositions, vaccines and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions, vaccines or kits as disclosed herein for use in the treatment and/or prophylaxis of cancer and related diseases.Type: ApplicationFiled: April 21, 2017Publication date: November 14, 2019Inventors: Mariola FOTIN-MLECZEK, Ingmar HOERR
-
Publication number: 20190314496Abstract: The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule.Type: ApplicationFiled: June 18, 2019Publication date: October 17, 2019Applicant: CureVac AGInventors: Mariola FOTIN-MLECZEK, Regina HEIDENREICH
-
Patent number: 10434158Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.Type: GrantFiled: February 7, 2018Date of Patent: October 8, 2019Assignee: CureVac AGInventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jochen Probst
-
Publication number: 20190241633Abstract: The present invention relates to an RNA encoding a therapeutic protein. In particular, the present invention relates to RNA suitable for use as a medicament. The present invention concerns such novel RNA as well as compositions and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions or kits as disclosed herein for use as a medicament. The present invention also provides the use of the RNA, compositions or kits as disclosed herein far increasing the expression of said encoded protein, in particular in gene therapy.Type: ApplicationFiled: May 4, 2017Publication date: August 8, 2019Inventors: Mariola FOTIN-MLECZEK, Ingmar HOERR
-
Patent number: 10369216Abstract: The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule.Type: GrantFiled: April 1, 2015Date of Patent: August 6, 2019Assignee: CureVac AGInventors: Mariola Fotin-Mleczek, Regina Heidenreich
-
Publication number: 20190194760Abstract: The present invention relates to methods of diagnosing, monitoring of a subject or determining the prognosis of a subject. In particular, the invention relates to a method of determining the prognosis of a cancer patient comprising the steps (a) determining the expression level of at least one marker gene selected from the group consisting of the marker genes as described herein in a sample of the cancer patient to obtain a gene expression profile; (b) determining the prognosis of the cancer patient based on the gene expression profile obtained in step (a). In addition, the present invention refers to kits, diagnostic compositions devices and microarrays for determining at least one marker gene and uses thereof.Type: ApplicationFiled: May 24, 2017Publication date: June 27, 2019Inventors: Sven KOCH, Henoch HONG, Mariola FOTIN-MLECZEK